Mayo Biotech Ovagen Raises €2M for Vaccine Development and Workforce Expansion

Tuesday, 29 October 2024, 07:02

Mayo Biotech Ovagen raises €2M to further its groundbreaking work in vaccine development using germ-free eggs. The funding will support plans to hire 60 new employees. This investment marks a significant milestone in advancing biotechnology and healthcare innovation.
Siliconrepublic
Mayo Biotech Ovagen Raises €2M for Vaccine Development and Workforce Expansion

Mayo Biotech Ovagen Secures Funding

Mayo Biotech Ovagen has successfully raised €2M in a recent investment round led by the WDC. This funding will enhance the company's development of world’s first germ-free eggs specifically for vaccine research.

Expansion Plans

  • New hires: Ovagen plans to add 60 employees to its team.
  • Focus on improving production and innovation in biotechnology.

The advancements in vaccine technology underscore the vital role of funding and workforce advancement in the field.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe